Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Ion Channels as Therapeutic Targets in Human Immunodeficiency Virus Associated Neuropathic Pain
FY 2013-14
Summary
AIDS patients frequently suffer from neurological disease as a result of infection by the human immunodeficiency virus (HIV). One in two patients suffers from chronic pain. Unlike many forms of serious pain which respond to morphine and other drugs, HIV associated “neuropathic” pain fails to respond to currently available drugs. The urgency to develop new therapies for HIV/AIDS associated pain is underlined by the alteration in the presentation of neuropathic pain in HIV infection that has occurred over the past decade. Whereas HIV/AIDS was once almost universally fatal, it now appears as a chronic disease. This is because the implementation of highly active antiretroviral therapy has greatly extended the life expectancy of those afflicted. Chronic, intractable pain thus persists for 20 years or more in these patients.
We know that HIV promotes the production of toxic proteins which damage sensory pain nerves whilst causing them to generate pain impulses which constantly enter the spinal cord and brain. To find out how this happens, we will first explore the actions of a toxic viral protein called viral protein R (Vpr). We will use electrical recordings of sensory nerve activity in the presence and absence of the protein to determine which ion channels are affected. Ion channels are protein pores in nerve cell membranes which control their electrical activity and enable them to generate nerve impulses. We will then use drugs such as “ K+ channel activators” to correct the effects of Vpr on sensory neuron activity. Mice which have been genetically engineered to make the viral protein Vpr (in the absence of HIV infection) display pain-related behaviours. We will see if the drugs that correct Vpr induced changes in sensory nerve activity can also stop pain in these animals. The anticipated findings of this study will thus be critical to our overall aim of developing urgently needed new approaches to treatment of neuropathic pain in a highly vulnerable population with a genuine opportunity for translation of the findings into improved health for Canadians.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311704
Name
Noh Myung-chul
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Ion Channels as Therapeutic Targets in Human Immunodeficiency Virus Associated Neuropathic Pain
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Distal Sensory Polyneuropathy; Dorsal Root Ganglia; Electrophysiology; Human Immunodeficiency Virus; Ion Channels; Neuropathic Pain; Patch Clamping; Pharmacology; Transgenic Mice; Viral Protein R
Abstract
AIDS patients frequently suffer from neurological disease as a result of infection by the human immunodeficiency virus (HIV). One in two patients suffers from chronic pain. Unlike many forms of serious pain which respond to morphine and other drugs, HIV associated “neuropathic” pain fails to respond to currently available drugs. The urgency to develop new therapies for HIV/AIDS associated pain is underlined by the alteration in the presentation of neuropathic pain in HIV infection that has occurred over the past decade. Whereas HIV/AIDS was once almost universally fatal, it now appears as a chronic disease. This is because the implementation of highly active antiretroviral therapy has greatly extended the life expectancy of those afflicted. Chronic, intractable pain thus persists for 20 years or more in these patients.
We know that HIV promotes the production of toxic proteins which damage sensory pain nerves whilst causing them to generate pain impulses which constantly enter the spinal cord and brain. To find out how this happens, we will first explore the actions of a toxic viral protein called viral protein R (Vpr). We will use electrical recordings of sensory nerve activity in the presence and absence of the protein to determine which ion channels are affected. Ion channels are protein pores in nerve cell membranes which control their electrical activity and enable them to generate nerve impulses. We will then use drugs such as “ K+ channel activators” to correct the effects of Vpr on sensory neuron activity. Mice which have been genetically engineered to make the viral protein Vpr (in the absence of HIV infection) display pain-related behaviours. We will see if the drugs that correct Vpr induced changes in sensory nerve activity can also stop pain in these animals. The anticipated findings of this study will thus be critical to our overall aim of developing urgently needed new approaches to treatment of neuropathic pain in a highly vulnerable population with a genuine opportunity for translation of the findings into improved health for Canadians.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Noh, Myung-chul
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~